Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve “safe” growth hormone levels. - Lindsay,JR.; MacConnell,EM.; Hunter,SJ.; MacCance,DR.; Sheridan,B.; Atkinson,AB. (Pituitary, 2004)